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ABSTRACT Heterodimers of types I and II serine/thre-
onine kinase receptor monomers compose the active receptor
complex for ligands ofthe transforming growth factor 3 family.
Here we show that the genomic organization of coding se-
quences for the intracellular domain of a widely expressed type
I serine/threonine kinase receptor is similar to that of the
activin type II receptor gene. The genomic structure and cDNA
clones indicate that poly(A) addition to alternative exons at
each of three carboxyl-terminal coding exonintron junctions
may be a common feature of both type I and II receptor genes.
The predicted products are monomers truncated at kinase
subdomains VII, IX, and X which vary in kinase activity and
potential serine, threonine, and tyrosine phosphorylation sites.
These results suggest that combinations of variants that affect
the signal-transducing intracellular kinase domain of both type
I and II receptor monomers within the transforming growth
factor 13 ligand family may add to the heterogeneity of biolog-
ical effects of individual ligands in the family.
Transmembrane serine (Ser)/threonine (Thr) protein kinases
participate in oligomeric receptor complexes that mediate the
activity of ligands within the transforming growth factor 83
(TGF,B) superfamily of cytokines (1-4). Two distinct sub-
branches of Ser/Thr kinase receptors constitute distinct
TGFB and activin type I and type II binding sites which can
be distinguished by size of the covalently crosslinked ligand-
receptor complexes. In mammals, five genetically distinct
Ser/Thr kinase receptors (SKRs) have been described which
are candidates for type I receptors (2-7), while type II
receptors for activin (ActRII and ActRIIB) and TGF,31
(TGFl3RII) have been characterized (8, 9). The TGFPRII and
ActRII receptor kinases are specific for TGFB and activin,
respectively, while some type I SKRs appear to crossreact
with both TGFB and activin dependent on the type II receptor
with which they form a complex (refs. 2-4, 8, and 9; unpub-
lished results).
In tyrosine kinase transmembrane receptors, ligand-
enhanced stabilization of dimerization of noncatalytic extra-
cellular domains facilitates intermolecular transphosphory-
lation of tyrosines within the substrate-binding and catalytic
intracellular domains (10). Transphosphorylation of specific
tyrosines is obligatory for binding, phosphorylation, or acti-
vation of specific substrates (10-14). Kinase- and phosphor-
ylation site-deficient monomers with an intact extracellular
dimerization domain act as dominant negative inhibitors of
function by competition with the formation of active ho-
modimeric complexes (14). In the fibroblast growth factor
receptor (FGFR) kinase family, alternative splicing results in
monomers from the same gene with altered kinase activity
and tyrosine phosphorylation sites (14-16). An alternative 5'
donor-site splice results in a kinase- and phosphorylation
site-defective isoform which combines with a dimerization-
competent extracellular domain with low affinity for ligand
(14, 15). Exon skipping results in a largely intact intracellular
kinase domain with a deletion of the specific tyrosine in the
carboxyl terminus that, when phosphorylated, is required for
binding of phospholipase Cyl (16). In addition to mRNA
coding for the complete 11 subdomains ofthe ActRII Ser/Thr
kinase, an isoform is expressed in Xenopus embryos which
exhibits only subdomains I-VII (17). The variant arises by
addition of a poly(A) tract to an alternatively spliced exten-
sion of the 3' end of the homolog of exon 8 in the mouse
ActRII gene (18). Here we report variant mRNAs in coding
sequence for the intracellular kinase domain of a widely
expressed human type I Ser/Thr kinase, SKR2. Cloning and
sequence analysis ofthe human SKR2 gene revealed a similar
genomic structuret coding for the intracellular kinase domain
and that alternative polyadenylylation and alternative splic-
ing at the 3' end ofexons 8, 9, and 10 may be a general feature
of receptors for the TGF(3 ligand superfamily.
MATERIALS AND METHODS
Analysis ofcDNAs. A 156-bp SKR2 cDNA was cloned from
aPCR using cDNA template from human hepatoma cell (Hep
G2) poly(A)+ RNA (5). Rapid amplification of cDNA ends
(RACE)-PCR (19) was carried out to identify the 5' end ofthe
SKR2 cDNA, using the SKR2-specific 3' primer P10 (5'-
TATAGAATTCTATGGCACACATGCCATTT-3').
To determine the complete coding sequence of the SKR2
cDNA, cDNAs were isolated from a Agtll phage library of
Hep G2 cell cDNAs (Clontech) by screening by both the PCR
method described previously (5) and with partial SKR2
cDNAs.
Analysis of Genomic DNA. A 1269-bp genomic DNA frag-
ment was generated and cloned by using paired primers P22
and P5 and a DNA template from a phage library prepared
from human leukocyte genomic DNA (Clontech) (5). The
DNA was used as a probe to identify two clones from about
106 phage. Both clones contained inserts of about 15 kb which
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transforming growth factor (3; TGF.3RII, TGFB receptor type II;
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exhibited identical restriction patterns when subjected to Xho
I, BamHI, EcoRI, and Xba I (see Fig. 2). DNA fragments of
1.8 kb (BamHI-BamHI), 2.65 kb (BamHI-Xba I), 5.1 kb (Xba
I-EcoRI), and 2.2 kb (EcoRI-Xho I) were subcloned into
pBluescript II SK vector (Stratagene). The sequence of each
DNA fragment was determined by analysis of a nested set of
shorter subclones that were generated with the Erase-a-Base
kit (Promega). Exons were identified by overlap with cDNA
sequences. Exon 11, which encodes kinase subdomain XI
(see Figs. 1 and 2) was first identified by homology of the
deduced amino acid sequences with human SKR1 (5) and rat
SKR2 (6) and later was confirmed at the mRNA level by PCR.
Analysis of mRNA. Expression of the SKR2 gene was
analyzed by RNase protection (RPA) with the MAXIscript
and RPAII kits (Ambion, Austin, TX). Total RNA (20 ,g)
isolated by the RNAzol method (Cinna/Biotecx Laborato-
ries, Friendswood, TX) from the indicated cells and tissues
was used. A 240-nt RNA probe complementary to an invari-
ant coding sequence in human SKR2 mRNA was transcribed
by T7 polymerase from an SKR2 cDNA template in the
pBluescript SK vector. The probe was complementary to a
178-bp coding sequence which began in the SKR2 extracel-
lular domain at an Xmn I site and extended through the
middle of the transmembrane domain. The probe also con-
tained 62 bp from the vector. For analysis of rat SKR2
mRNA, a rat SKR2 cDNA fragment spanning coding se-
quence for the SKR2 extracellular and transmembrane do-
mains was generated by PCR with human primers P18 and
P19 using rat prostate cDNA template. The resulting 469-bp
cDNA fragment was subcloned into the EcoRI site of pBlue-
script SK and the sequence was determined. The cDNA was
used to generate a 295-nt cRNA probe with T3 polymerase
within which was a 201-nt rat sequence between Xmn I
restriction sites complementary to SKR2 coding sequence
extending from a point in the extracellular domain through
the transmembrane domain. The probe also contained 20 nt
of human sequence from primer P19 and 74 nt from the
vector. Human and mouse ,3-actin RNA probes were used as
positive controls for human and rat RPA, respectively. Yeast
RNA was used as a negative control.
Poly(A)+ RNA from Hep G2 cells was purified on oli-
go(dT)-cellulose (GIBCO/BRL) and used for both reverse
transcription for PCR and RPA. The SKR2-1 mRNA, which
encodes the full-length carboxyl terminus of SKR2, was
detected by paired 5' primer P9 (5'-AATGTCGACGTCAT-
GATGCAGTCACTGA-3') and 3' primer P60 (5'-TAG-
GATCCACAGAGGGCTGGGCAGAAAC-3'). P9 was com-
plementary to coding sequence within kinase subdomain VII.
P60 was complementary to a 3' noncoding sequence of
SKR2-1 which was 85-105 bp downstream of the translation
stop codon within exon 11. A 5' primer, P28 (5'-CTCGAA-
GATGCAATTCTGGA-3'), which was complementary to
sequence coding for subdomain IX was combined with an
SKR2-2 isoform-specific 3' primer, P30 (5'-TATGAATTCG-
TAGAGATGGGGGTCTCCCCACA-3'), or an SKR2-3 iso-
form-specific 3' primer, P29 (5'-TATGAATTCTTAACAAT-
GAAACAGCAGGGTT-3'), to detect mRNA encoding the
SKR2-2 and SKR2-3 variants, respectively. P30 and P29 were
complementary to nucleotide sequence just upstream of the
poly(A) tracts of the SKR2-2 and SKR2-3 cDNAs, respec-
tively.
DNA templates for making 32P-labeled cRNA probes to
analyze SKR2 variants by RPA were generated by PCR with
5' primer P28 and SKR2-2-specific 3' primer P34 (5'-
CGCGTAATACGACTCACTATAGGGCGAATTGGCAG-
GAGGCCAGCTTCTTACCTCATA-3') or SKR2-3-specific
3' primer P35 (5'-CGCGTAATACGACTCACTATAGGGC-
GAATTGCACAGCTACCTCCACACCTTTGATG-3'). A
T7 promoter sequence (underlined) and an unrelated 10 nt
(italics) were incorporated upstream of the sequences com-
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FIG. 1. Deduced sequences of human SKR2 variants. The amino acid sequences of SKR2-1, SKR2-2, and SKR2-3 were deduced from the
nucleotide sequences described in the text. Residues conserved among human SKR2 (GenBank nos. L10125 and L10126), SKR1 (ref. 5; GenBank
no. L02911), and TGF,6RII (ref. 9; GenBank no. M85079) are shown in reverse print. Conserved cysteine residues in the extracellular domain
(solid boxes), the transmembrane domain (boxed), intracellular Ser/Thr kinase subdomains (I-XI), conserved potential Ser/Thr (open circles)
and tyrosine (solid circles) phosphorylation sites, and the sites where the sequence of SKR2-2 (open triangle) and SKR2-3 (closed triangle) and
SKR2-4 (open diamond) diverge from SKR2-1 are indicated. The location and direction of nucleotide primers used in the study are also indicated.
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plementary to SKR2 in the 3' primers. A 182-nt cRNA probe
was transcribed with T7 RNA polymerase from the PCR-
derived template sequence between paired P28 and P34. The
cRNA probe consisted of a 153-nt sequence common to
SKR2-1 and SKR2-2 followed by 19 nt of SKR2-2-specific
sequence plus the unrelated 10-nt sequence in the template.
A 192-nt cRNA probe was transcribed with 17 polymerase
from the PCR-derived template resulting with P28 and P35.
The probe was composed of 22 nt of common SKR2 se-
quence followed by 160 nt of SKR2-3-specific sequence and
the unrelated 10-nt sequence from the template. The unre-
lated 10-nt sequence was incorporated in both templates to
distinguish protected RNA bands from the probe (see Fig. 4
D and E).
RESULTS
Identification and Characterization of the SKR2 cDNAs.
Application of the PCR and sequence analysis of a 156-bp
DNA fragment generated between degenerate primers com-
plementary to conserved subdomains VIB and VIII ofmouse
ActRII and Caenorhabditis elegans daf-) genes revealed a
distinct Ser/Thr kinase homologue, SKR2, of previously
reported SKR1 (5) from Hep G2 cells (Fig. 1). Application of
5'-RACE-PCR using 3' primer P10, which was complemen-
tary to coding sequence for kinase subdomain VII, yielded a
1061-bp cDNA beginning 7 bp upstream of the translational
initiation site. cDNA clones derived from a Hep G2 cDNA
phage library overlapped with and confirmed authenticity of
the cDNA generated by 5'-RACE-PCR. The phage clones
were used to deduce the carboxyl-terminal sequence ofSKR2
variants downstream of kinase subdomain VIII. The amino
A 1kb I I I
acid sequence deduced from overlapping 871-bp and 947-bp
cDNAs which exhibited poly(A) tails diverged beginning at
the end of kinase subdomains IX (SKR2-3) and X (SKR2-2),
respectively (Fig. 1). The 1795-bp SKR2-2 cDNA exhibited
an open reading frame encoding 476 aa extending through
kinase subdomain X followed by a 12-aa carboxyl-terminal
tail. The SKR2-3 cDNA exhibited 1301 bp in common with
SKR2-2 and a reading frame of 421 a4 which extended
through kinase subdomain IX followed by a 66-aa carboxyl-
terminal tail (Fig. 1). Kinase subdomain XI and the carboxyl-
terminal tail ofthe full-length SKR2 homolog (SKR2-1) (Figs.
1 and 2) were deduced from cloned SKR2 genomic DNAs
containing exon 11 as described below. While this study was
in progress and after the SKR2-2 and SKR2-3 sequences
reported here were released by the GenBank data base
(February 1993), He et al. (6) and ten Dijke et al. (7) reported
the cloning ofcDNAs for the rat and human SKR2-1 (ALK4)
isoform which extends through kinase subdomain XI and the
carboxyl-terminal tail.
Structure of the SKR2 Gene Coding for the Variant Car-
boxyl-Terminal Domains. The presence of significant poly(A)
tracts in cDNAs coding for the SKR2-2 and SKR2-3 variants
suggested that both may arise by alternative splicing and
poly(A) addition. To determine whether this hypothesis was
compatible with the structure of the SKR2 genome, genomic
DNA fragments spanning the coding sequence for the variant
SKR2 carboxyl-terminal domains were cloned from a library
of human leukocyte genomic DNAs. Preliminary restriction
and sequence (Fig. 2) analyses of two independent clones
with inserts of 15 kb suggested that exon-intron boundaries
were similar to those of the mouse ActRII gene (18), the only
member of the Thr/Ser kinase receptor family for which the
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FIG. 2. Genomic arrangement of coding sequences for the carboxyl-terminal domain of the SKR2 gene. (A) Schematic showing restriction
enzyme sites and the exon (solid and hatched) and intron (unshaded) relationships. The exons and introns were numbered according to the system
used for the ActRII gene (18). Alternative exons resulting in truncated variants are hatched. Stop codons for each variant are indicated. Exon
combinations for four potential SKR2 variants are indicated. (B) Sequence at exon-intron junctions ofexons coding for the full-length carboxyl
terminus of SKR2-1. Exon and intron sequences are indicated in uppercase and lowercase letters, respectively. Lengths of exons and introns
are indicated in base pairs. (C) Alternative terminal coding exons for truncated SKR2 variants. The length of alternative exons and between
the indicated sequences is shown in base pairs. Poly(A) tails (parentheses) on the cloned cDNAs for SKR2-2 and SKR2-3 are indicated.
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genomic structure has been reported. The 11-kb 3' sequence
covered five exons designated exons 7, 8a, 9a, 10a, and 11
(Fig. 2) which were counterparts of exons 7-11 of the ActRII
gene. Exons 7, 8a, 9a, 10a, and 11 encode the full-length
amino acid sequence of the SKR2-1 kinase, which includes
subdomains VI-A, VI-B, VII, VIII, IX, X, XI, and the
carboxyl-terminal tail. The SKR2-3 variant consisting of
exons 7, 8a, and alternative exon 9b apparently arises by
cleavage within intron 9 and poly(A) addition to alternative
exon 9b in response to a signal within intron 9. A reading-
frame shift beginning at the 3' end of exon 9a followed by an
in-frame downstream stop codon results in the unique 66-aa
carboxyl terminus lacking kinase subdomains X and XI
which characterizes the SKR2-3 isoform. Similarly, the
SKR2-2 variant apparently arises by cleavage within intron
10 and poly(A) addition to alternative exon 10b. A reading-
frame shift at the 3' end of exon 10a and a subsequent stop
codon results in the unique 12-aa carboxyl terminus of the
SKR2-2 isoform which lacks kinase subdomain XI. Although
it has not yet been confirmed by cDNA sequence or mRNA
expression analysis, the sequence analysis of the SKR2
genomic DNA indicates the potential for generation of an
additional variant tentatively designated SKR2-4 that arises
by cleavage and RNA chain termination within intron 8 and
poly(A) addition to resultant alternative exon 8b (Fig. 2). The
predicted translation product is a variant consisting of an
intracellular domain of only intact kinase subdomains I-VII
as a consequence of the presence of an in-frame stop codon
in resultant alternative exon 8b, just past the 3' end of exon
8a (Fig. 2C). Potential alternative exon 8b exhibits a perfect
consensus poly(A) addition signal 800 bp past the 3' end of
exon 8a.
Expression of SKR2. Nuclease protection analysis of total
RNA with a probe containing sequence complementary to
common sequences in all SKR2 isoforms revealed that the
SKR2 mRNA was widely expressed in cells and tissues from
human (Fig. 3A) and rat (Fig. 3B).
Expression of the SKR2-1, SKR2-2, and SKR2-3 variants
in Hep G2 cells was confirmed by analysis of purified mRNA
preparations [poly(A)+ RNA] with isoform-specific primers
in the PCR and RPA with variant-specific cRNA probes.
Primer pair P9/P60 revealed the 565-bp product indicative of
the presence of the SKR2-1 mRNA (Fig. 4A). Primer pairs
P28/P30 and P28/P29 revealed the expected 507-bp SKR2-2
and 434-bp SKR2-3 bands which specifically hybridized with
32P-labeled SKR2-2 and SKR2-3 cDNAs, respectively (Fig. 4
B and C). RPA further confirmed the expression of the SKR2
isoforms in Hep G2 cells (Fig. 4 D and E). Protection of 153-
and 172-nt fragments within a 182-nt cRNA probe designed to
detect SKR2-1 and SKR2-2 isoforms confirmed the presence
of both transcripts in mRNA preparations from Hep G2 cells
(Fig. 4D). Expression ofthe transcript for the SKR2-3 variant
was confirmed by protection of the expected (182-nt se-
quence) within a 192-nt cRNA probe designed to detect
specifically the SKR2-3 variant mRNA (Fig. 4E). The results
suggest that SKR2-1, -2-2, and -2-3 are expressed in Hep G2
cells from which their cDNAs were identified by PCR and
conventional cloning. The amount of SKR2-1 mRNA was
highest and that of SKR2-2 mRNA was lowest in Hep G2
cells. The SKR2-1 and SKR2-2, but not SKR2-3, mRNAs
have also been detected in human umbilical vein endothelial
cells (data not shown).
DISCUSSION
Here we show that the genomic structure coding for the
carboxyl-terminal intracellular domain of a widely expressed
type I SKR, SKR2, is similar to that reported for the type II
kinase receptor ActRII gene (18). Alternative splicing and
cleavage and poly(A) addition within introns at the 3' end of
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FIG. 3. Expression of SKR2 mRNA. (A) Human cells. Total
RNA (20 ,g) from the indicated cells was analyzed by the RNase
protection method. "Probe (A)" and "probe" indicate the labeled
3-actin (230-nt) and SKR2 (240-nt) cRNA probes, respectively, in the
absence of RNA. Probe (A) contained 137 nt of the human ,3actin
sequence. Hep G2 and Hep 3B, well-differentiated hepatocyte-like
hepatoma cells; A431, cervical carcinoma epithelial cells; HUVEC,
human umbilical vein endothelial cells; HF, human fibroblasts (Flow
2000) derived from lung; HeLa, cervical carcinoma epithelial cells.
(B) Rat tissues and rat prostate tumor cells. RNA from the indicated
tissues and cells were analyzed with a 295-nt cRNA probe. The probe
contained 20 nt of human SKR2 sequence in addition to the 201-nt rat
SKR2 sequence (Materials and Methods), which resulted in variable
levels of protected 221-nt band due to mismatch between the human
and rat sequences. RNA loads were normalized with a 300-nt mouse
,-actin cRNA probe which crossreacts with rat P-actin mRNA to
protect a 250-nt fragment.
the last two coding exons (exons 9a and lOa) for the full-
length carboxyl terminus of SKR2 results in variants pre-
dicted to be devoid of kinase subdomains XI (SKR2-2) and X
and XI (SKR2-3), respectively. Although expression of an
mRNA has not been confirmed, the presence of a perfect
poly(A) addition signal within intron 8 downstream of exon 8a
suggests that an SKR2 mRNA may arise similar to that
reported for the ActRII gene, which lacks the coding se-
quence for kinase subdomains VIII-XI (17).
Tyrosine kinase receptors are composed of homodimers in
which one or more tyrosines within a monomer are obliga-
torily substrates of the adjacent kinase within the homodimer
(10-14). In the FGFR tyrosine kinase family, kinase- and
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FIG. 4. Expression of SKR2 variants in Hep G2 cells. (A-C) Expression of the indicated variants analyzed by PCR with isoform-specific
primer pairs (Fig. 1 and Materials and Methods) P9/P60 (A), P28/P30 (B), and P28/P29 (C). Lanes 1, 5, and 8, cDNA template prepared by
reverse transcription of poly(A)+ RNA; lanes 3 and 6, positive controls (cloned SKR2-2 and SKR2-3 cDNA templates, respectively); lanes 2,
4, and 7, negative controls (no reverse transcription product). A is an agarose gel stained with ethidium bromide. B and C are autoradiographs
of Southern blots hybridized with 32P-labeled SKR2-2 and SKR2-3 cDNAs, respectively. (D and E) RPA of SKR2 variants. Lane 9, a 182-nt
cRNA probe containing 153 nt complementary to sequences common to SKR2-1 and SKR2-2 and 19 nt complementary to the unique SKR2-2
sequence; lane 11, a 192-nt cRNA probe consisting of 22 nt complementary to common SKR2 sequence and 160 nt complementary to specific
SKR2-3 sequence; lanes 10 and 12, yeast RNA (YRNA) instead of poly(A)+ RNA (5 ug). Results in D and Ewere obtained with the same mRNA
preparation hybridized with probes of similar specific activity and are from the same film exposed for the same period.
phosphotyrosine site-defective monomers that arise by alter-
native splicing depress signal transduction by dimerization
with monomers with intact kinase activity and phosphoty-
rosine sites (11, 14-16). In contrast, receptors for the TGFB
family are composed of heterodimers of two genetically
distinct Ser/Thr kinases (types II and I) both of which are
obligatory for biological activity (1-4). The type II compo-
nent is specific for individual members of the TGFB ligand
family, whereas some type I components are shared among
multiple members of the ligand family (refs. 1-4, 8, and 9;
unpublished results). Our results, together with those re-
ported for the ActRII gene (17), suggest that monomers with
four variant intracellular domains of both type I and specific
type II components potentially add to the heterogeneity of
the heterodimeric receptor complex for a single member of
the TGFB ligand family. Expression of artificial construc-
tions of the TGFI3RII and ActRII receptors which are devoid
of the complete intracellular kinase domain appear to depress
ligand-induced activities in Xenopus embryos (20) or trans-
fected cells (21, 22). However, the truncated isoform of the
ActRII receptor exhibiting kinase domains I-VII which
arises as a result of alternative splicing ofintron 8 and poly(A)
addition exhibits a positive activity that exceeds that of intact
ActRIl in Xenopus embryos (17). Truncated forms of ActRII
and SKR2 (SKR2-2 and SKR2-3) are devoid of domains
demonstrated to be essential in other kinases and are unlikely
to exhibit full kinase activity. What then might be the function
of sequentially truncated kinase-defective monomeric recep-
tor isoforms? The intrinsic kinase activity of epidermal
growth factor receptor kinase monomers appears to be un-
essential for activation of the MAP-2 kinase pathway, pro-
vided that tyrosine sites essential for binding of substrates
which initiate the pathway are phosphorylated by a receptor
monomer with intact kinase activity (23). Truncated kinase-
inactive type I and type II monomeric receptors for the TGF,3
ligands may play a role as asymmetric substrates of an active
kinase monomer within type II-type I heterodimers. Trun-
cated monomers predicted from cDNA differ by potential
serine, threonine, or tyrosine phosphorylation sites around
which different substrates may assemble (Fig. 1).
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